StreetInsider.com News Articles

Protagonist Therapeutics (PTGX) PT Raised to $165 at Citizens as Icotyde Revenue Ramps

Fri, 17 Jul 2026 05:06:43 -0400

Citizens analyst Jonathan Wolleben raised the price target on Protagonist Therapeutics (NASDAQ: PTGX) to $165.00 (from $137.00) while maintaining a Market Outperform rating.

The analyst commented, "We reiterate our Market Outperform rating and raise our risk-adjusted, DCF-derived PT on Protagonist Therapeutics to $165 from $137. JNJ did not report 2Q Icotyde (icotrokinra) sales but noted 11K prescriptions have been written, and with a monthly WAC of $8,285 – 11K patients would annualize to ~$1B in sales before any discounts. We had not modeled any Icotyde royalty revenue in 2Q, which we now estimate at ~$8M, and we accelerate our Icotyde royalty

Protagonist Therapeutics (PTGX) PT Raised to $165 at Citizens as Icotyde Revenue Ramps

Fri, 17 Jul 2026 05:06:43 -0400

Citizens analyst Jonathan Wolleben raised the price target on Protagonist Therapeutics (NASDAQ: PTGX) to $165.00 (from $137.00) while maintaining a Market Outperform rating.

Protagonist Therapeutics Reports Granting of Inducement Awards

Thu, 16 Jul 2026 16:05:00 -0400

NEWARK, CA / ACCESS Newswire / July 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 15, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

The new employees received, in the aggregate, options to purchase 12,600 shares of Protagonist Therapeutics common stock and restricted stock units (RSUs) to acquire 3,330

Protagonist Therapeutics Reports Granting of Inducement Awards

Thu, 16 Jul 2026 16:05:00 -0400

The new employees received, in the aggregate, options to purchase 12,600 shares of Protagonist Therapeutics common stock and restricted stock units (RSUs) to acquire 3,330

Protagonist Therapeutics (PTGX) PT Raised to $151 at Barclays

Tue, 14 Jul 2026 05:13:51 -0400

Barclays analyst Etzer Darout raised the price target on Protagonist Therapeutics (NASDAQ: PTGX) to $151.00 (from $119.00) while maintaining a Overweight rating.

Protagonist Therapeutics (PTGX) PT Raised to $145 at Truist Securities

Tue, 07 Jul 2026 06:03:32 -0400

Truist Securities analyst Srikripa Devarakonda raised the price target on Protagonist Therapeutics (NASDAQ: PTGX) to $145.00 (from $121.00) while maintaining a Buy rating.

The analyst comments "We reiterate our Buy rating of PTGX as we continue to be bullish on broader Icotyde commercial opportunity. Johnson & Johnson (JNJ, NR) commentary on Icotyde continues to indicate 1) rapid access and uptake for the drug in Psoriasis; 2) strong KOL enthusiasm driven by label strength, & 3) comments around Ico potential to be "one of their biggest products ever", raising overall peak sales estimates beyond $10B. We have updated our model to reflect

Protagonist Therapeutics (PTGX) PT Raised to $145 at Truist Securities

Tue, 07 Jul 2026 06:03:32 -0400

Truist Securities analyst Srikripa Devarakonda raised the price target on Protagonist Therapeutics (NASDAQ: PTGX) to $145.00 (from $121.00) while maintaining a Buy rating.

Protagonist Therapeutics Reports Granting of Inducement Awards

Wed, 01 Jul 2026 16:05:00 -0400

NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 30, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

The new employees received, in the aggregate, options to purchase 8,650 shares of Protagonist Therapeutics common stock and restricted stock units (RSUs) to acquire 2,275

Protagonist Therapeutics Reports Granting of Inducement Awards

Wed, 01 Jul 2026 16:05:00 -0400

The new employees received, in the aggregate, options to purchase 8,650 shares of Protagonist Therapeutics common stock and restricted stock units (RSUs) to acquire 2,275

TD Cowen Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

Wed, 01 Jul 2026 09:13:48 -0400

TD Cowen analyst Tara Bancroft reiterated a Buy rating and $100.00 price target on Protagonist Therapeutics (NASDAQ: PTGX).

The analyst commented: "Mgmt Thoughts On Upcoming PN-881 Data In Q3 & Ico/Rusfertide Launches; We spoke with management about the PN-881 (oral IL-17) update in Q3, where direct advancement into a PsO Phase IIb would be the best case (and in our view, most likely) scenario. 60-70% responses in PsO may be ultimately likely. The Ico launch is accelerating and extending beyond Otezla switches. Rusfertide's approval (August PDUFA) should lead to a robust launch supported by plenty of confidence."

For an analyst ratings summary

Form 4 Protagonist Therapeutics For: Jun 23 Filed by: Waddill William D.

Thu, 25 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260625/26692405.html

Form 4 Protagonist Therapeutics For: Jun 23 Filed by: Waddill William D.

Thu, 25 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260625/26692405.html

Form 144 Protagonist Therapeutics Filed by: Waddill William D.

Tue, 23 Jun 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260623/26679835.html

Form 144 Protagonist Therapeutics Filed by: Waddill William D.

Tue, 23 Jun 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260623/26679835.html

Form 8-K Protagonist Therapeutics For: Jun 17

Thu, 18 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260618/26666610.html

Form 8-K Protagonist Therapeutics For: Jun 17

Thu, 18 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260618/26666610.html

Protagonist Therapeutics Reports Granting of Inducement Awards

Tue, 16 Jun 2026 16:00:00 -0400

NEWARK, CA / ACCESS Newswire / June 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 15, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

The new employees received, in the aggregate, options to purchase 14,800 shares of Protagonist Therapeutics common stock and restricted stock units (RSUs) to acquire 3,900

Protagonist Therapeutics Reports Granting of Inducement Awards

Tue, 16 Jun 2026 16:00:00 -0400

The new employees received, in the aggregate, options to purchase 14,800 shares of Protagonist Therapeutics common stock and restricted stock units (RSUs) to acquire 3,900

Form 4 Protagonist Therapeutics For: Jun 10 Filed by: Waddill William D.

Thu, 11 Jun 2026 19:07:00 -0400

si-local-file:///var/storage/secattach/20260611/26637149.html

Form 4 Protagonist Therapeutics For: Jun 10 Filed by: Waddill William D.

Thu, 11 Jun 2026 19:07:00 -0400

si-local-file:///var/storage/secattach/20260611/26637149.html

Form 144 Protagonist Therapeutics Filed by: Waddill William D.

Wed, 10 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260610/26630308.html

Form 144 Protagonist Therapeutics Filed by: Waddill William D.

Wed, 10 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260610/26630308.html

Form 4 Protagonist Therapeutics For: May 29 Filed by: Waddill William D.

Mon, 01 Jun 2026 18:31:00 -0400

si-local-file:///var/storage/secattach/20260601/26585481.html

Form 4 Protagonist Therapeutics For: May 29 Filed by: Waddill William D.

Mon, 01 Jun 2026 18:31:00 -0400

si-local-file:///var/storage/secattach/20260601/26585481.html

Form 144 Protagonist Therapeutics Filed by: Waddill William D.

Fri, 29 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260529/26575554.html